OBJECTIVES: To test neurocognitive function in patients with late-onset Tay-Sachs disease (LOTS) using a computerized system to assess whether cognition is a clinically relevant outcome measure of possible therapeutic intervention in LOTS. METHODS: Ten adults with Tay-Sachs disease were administered at least one battery of the Mindstreams Neurotrax system for evaluation of cognitive function. Six sub-scores and a Global Cognitive Score (GCS) were tabulated. A disease specific severity score was also devised with six domains. RESULTS: Despite identical genotypes, all patients but the two oldest had > or = 3/6 sub-scores one standard deviation below normal mean (100); verbal and executive functions were most affected. The severity score measured other functions. CONCLUSIONS: Because of provocative findings on re-testing in patients exposed to miglustat, and despite the very small cohort, cognitive function may be an appropriate and clinically relevant outcome measure for future therapeutic interventions in LOTS.
OBJECTIVES: To test neurocognitive function in patients with late-onset Tay-Sachs disease (LOTS) using a computerized system to assess whether cognition is a clinically relevant outcome measure of possible therapeutic intervention in LOTS. METHODS: Ten adults with Tay-Sachs disease were administered at least one battery of the Mindstreams Neurotrax system for evaluation of cognitive function. Six sub-scores and a Global Cognitive Score (GCS) were tabulated. A disease specific severity score was also devised with six domains. RESULTS: Despite identical genotypes, all patients but the two oldest had > or = 3/6 sub-scores one standard deviation below normal mean (100); verbal and executive functions were most affected. The severity score measured other functions. CONCLUSIONS: Because of provocative findings on re-testing in patients exposed to miglustat, and despite the very small cohort, cognitive function may be an appropriate and clinically relevant outcome measure for future therapeutic interventions in LOTS.
Authors: Orit Neudorfer; Gregory M Pastores; Bai J Zeng; John Gianutsos; Charles M Zaroff; Edwin H Kolodny Journal: Genet Med Date: 2005-02 Impact factor: 8.822
Authors: F M Platt; G R Neises; G Reinkensmeier; M J Townsend; V H Perry; R L Proia; B Winchester; R A Dwek; T D Butters Journal: Science Date: 1997-04-18 Impact factor: 47.728
Authors: E Hund; A Grau; W Fogel; M Forsting; M Cantz; B Kustermann-Kuhn; K Harzer; R Navon; H H Goebel; H M Meinck Journal: J Neurol Sci Date: 1997-01 Impact factor: 3.181
Authors: Christopher D Stephen; David Balkwill; Peter James; Elizabeth Haxton; Kenneth Sassower; Jeremy D Schmahmann; Florian Eichler; Richard Lewis Journal: Neurology Date: 2020-01-21 Impact factor: 9.910
Authors: Olivia E Rowe; D Rangaprakash; Akila Weerasekera; Neha Godbole; Elizabeth Haxton; Peter F James; Christopher D Stephen; Robert L Barry; Florian S Eichler; Eva-Maria Ratai Journal: Mol Genet Metab Date: 2021-06-24 Impact factor: 4.204